HC Wainwright Has Positive Outlook of AMLX FY2028 Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Research analysts at HC Wainwright lifted their FY2028 earnings estimates for Amylyx Pharmaceuticals in a research report issued on Tuesday, August 18th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.97) per share for the year, up from their prior forecast of ($1.08). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2029 earnings at $3.22 EPS and FY2030 earnings at $6.40 EPS.

AMLX has been the topic of several other reports. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Guggenheim lifted their price target on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Citigroup upped their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $36.25.

Amylyx Pharmaceuticals Trading Up 9.9%

AMLX opened at $38.60 on Thursday. The firm has a market capitalization of $4.30 billion, a PE ratio of -26.99 and a beta of -0.21. Amylyx Pharmaceuticals has a 12-month low of $7.82 and a 12-month high of $39.07. The firm has a 50 day moving average of $19.38 and a two-hundred day moving average of $16.35.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03).

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the sale, the insider owned 194,090 shares in the company, valued at $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.90% of the stock is owned by corporate insiders.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. KBC Group NV purchased a new stake in Amylyx Pharmaceuticals in the 1st quarter valued at about $26,000. Meeder Asset Management Inc. purchased a new position in Amylyx Pharmaceuticals during the fourth quarter worth about $25,000. State of Wyoming purchased a new position in Amylyx Pharmaceuticals during the second quarter worth about $40,000. Caitong International Asset Management Co. Ltd increased its position in shares of Amylyx Pharmaceuticals by 954.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after acquiring an additional 3,493 shares during the last quarter. Finally, California State Teachers Retirement System acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at about $28,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals News Roundup

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Phase 3 LUCIDITY success supports avexitide approval prospects. Amylyx reported that avexitide met the primary and secondary endpoints in the LUCIDITY trial for post-bariatric hypoglycemia, reducing hypoglycemic events by 55%. The results could support an FDA filing by the end of 2026 and advance the company’s first potential commercial product. Reuters article
• Positive Sentiment: Analysts raised price targets and ratings. Guggenheim increased its target to $55 from $40 with a Buy rating, while Robert W. Baird raised its target to $52 from $28 with an Outperform rating. Wolfe Research also upgraded the stock to Strong Buy. HC Wainwright retained a Buy rating and a $55 target. Benzinga analyst coverage
• Positive Sentiment: Long-term earnings estimates improved significantly. HC Wainwright raised its FY2029 EPS forecast to $3.22 from $1.66 and its FY2030 estimate to $6.40 from $3.74. The revisions suggest analysts see greater commercial potential for avexitide and a faster path to profitability.
• Neutral Sentiment: Shares are trading near the top of their 52-week range. The new high reflects strong investor momentum following the trial announcement, although the stock’s valuation and future performance now depend heavily on regulatory progress, commercialization, and execution.
• Negative Sentiment: Amylyx is raising substantial capital, creating dilution risk. The company priced an upsized underwritten offering of 14.09 million shares at $35.50 each, expected to raise approximately $500 million before expenses. Underwriters may purchase an additional 2.11 million shares, which could dilute existing shareholders even as the proceeds strengthen Amylyx’s balance sheet. Amylyx public offering announcement

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs.